View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Seafood Research ... (+3)
  • ABGSC Seafood Research
  • Martin Kaland
  • Simon Brun
ABGSC Seafood Research ... (+3)
  • ABGSC Seafood Research
  • Martin Kaland
  • Simon Brun
ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland
Håkon Astrup
  • Håkon Astrup

Storebrand (Buy, TP: NOK149.00) - Insurance repricing on track

Q1 PTP before amortisation was NOK1,167m, up 8% YOY, driven by strong growth in Banking and Insurance. While high sales activity had a negative impact on the insurance cost ratio, the combined ratio continued to improve through premium growth of 20% YOY, leaving Storebrand close to the 90–92% target for 2025. We have made fairly limited EPS revisions for 2026–2027e, and reiterate our BUY and NOK149 target price.

ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland

Softer operating profit, better financials

Adj PTP +5%/-2%, on better financials, but much weaker op.profit. Softer fee, insurance and opex behind the miss, financials beat. Cons.est.rev -2-4%, stock -2% to 4% on the operating profit miss

ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland
Simen Mortensen
  • Simen Mortensen

More Q1 results and a proposed delisting

The Q1 reporting season is in full swing, with results from Catena, Entra, Pandox and Wihlborgs in the past week. In addition, Aurora Eiendom announced a proposal to delist from Euronext Growth Oslo. The weighted-average implied EBITDA yields on the stocks we cover are 5.00% for 2025e and 5.31% for 2026e.

 PRESS RELEASE

Kaldvik AS – Trading update Q1 2025

Kaldvik AS – Trading update Q1 2025 Harvested volume for Q1 2025 was 6.383 tonnes gutted weight (GWT). The complete report for Q1 2025 will be published May 21th 2025.For further information, please contact:Róbert Róbertsson, CFO of Kaldvik AS: (mobile) About Kaldvik ASKaldvik AS is one of the leading salmon farmers in Iceland. Kaldvik AS has a well-developed and fully integrated value-chain controlling all steps from hatchery to sales, enabling the group to provide its customers with a sustainable premium product. Kaldvik AS is dual-listed on Euronext Growth Oslo and First North Iceland G...

ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland
ABGSC Financials Research ... (+3)
  • ABGSC Financials Research
  • Fredrik Flørnes Støle
  • Jan Erik Gjerland
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
Karl-Johan Bonnevier
  • Karl-Johan Bonnevier

Humana (Buy, TP: SEK52.00) - Growth agenda back in focus

The Q1 results were mixed, but with the financials now in good order, we see more of a growth focus ahead. We find management’s priorities logical, with our underlying forecast largely unchanged, but our 2025–2027e EPS cut by 6–2% on FX and non-cash items. We reiterate our BUY, but have trimmed our target price to SEK52 (53), focusing on Humana’s market opportunity, operating profile, financial outlook and valuation.

 PRESS RELEASE

New share capital registered

New share capital registered Frøya, Norway, 26 April 2025: Reference is made to the stock exchange announcement by Kaldvik AS ("Kaldvik", the "Company") on 22 April 2025, regarding the issuance of new shares in connection with the acquisition of key assets in the fish farming value chain on the east-coast of Iceland. The share capital increase has now been registered with the Norwegian Register of Business Enterprises. The Company’s new registered share capital is NOK 12,851,120.10, divided on 128,511,201 shares, each carrying one vote at the Company’s general meeting and each with a nom...

Simen Mortensen
  • Simen Mortensen

Signs of sector recovery, and more Q1 results

The markets were much quieter following the Easter break, with limited news; however, the names we cover saw their shares up 2.6% on average, with Atrium Ljungberg (7.1%), SBB (7.1%) and Pandox (4.8%) the top performers. JM released its Q1 results and we reiterated our BUY, believing it has passed the earnings trough, while we reiterated our HOLDs on Corem and Fabege following their quarterly reports. The weighted-average implied EBITDA yields on the stocks we cover are 5.04% for 2025e and 5.34%...

Helene Kvilhaug Brøndbo
  • Helene Kvilhaug Brøndbo

Cambi (Buy, TP: NOK24.00) - Keeps adding backlog

Ahead of Q1 results, we forecast EBITDA of NOK49m (no consensus available). We believe Cambi is progressing well with three contract additions and one expansion, underpinning the strong market potential, and see opportunities for further additions in the not-too-distant future. We reiterate our BUY and NOK24 target price, and view the stock as attractive, trading at 2025–2027e P/Es of 15–9x.

ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Julia Sundvall
  • Stefan Knutsson
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch